2seventy bio (NASDAQ:TSVT - Get Free Report)'s stock had its "sell (d-)" rating reiterated by stock analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.
2seventy bio Trading Down 1.6 %
Shares of TSVT stock traded down $0.04 during trading hours on Wednesday, hitting $2.64. The company's stock had a trading volume of 149,163 shares, compared to its average volume of 293,090. The business has a fifty day moving average of $2.70 and a 200-day moving average of $3.84. The stock has a market cap of $135.99 million, a price-to-earnings ratio of -1.40 and a beta of 1.74. 2seventy bio has a twelve month low of $2.29 and a twelve month high of $6.00.
Hedge Funds Weigh In On 2seventy bio
A number of large investors have recently bought and sold shares of TSVT. SG Americas Securities LLC purchased a new position in 2seventy bio during the third quarter worth approximately $80,000. GSA Capital Partners LLP purchased a new position in 2seventy bio during the third quarter worth approximately $64,000. Intech Investment Management LLC purchased a new position in 2seventy bio during the third quarter worth approximately $69,000. FMR LLC raised its stake in 2seventy bio by 22.0% during the third quarter. FMR LLC now owns 148,545 shares of the company's stock worth $701,000 after purchasing an additional 26,738 shares during the period. Finally, BBR Partners LLC raised its stake in 2seventy bio by 620.0% during the third quarter. BBR Partners LLC now owns 180,000 shares of the company's stock worth $850,000 after purchasing an additional 155,000 shares during the period. Hedge funds and other institutional investors own 93.90% of the company's stock.
2seventy bio Company Profile
(
Get Free Report)
2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.
See Also
Before you consider 2seventy bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 2seventy bio wasn't on the list.
While 2seventy bio currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
